PRTC News and Press, PureTech Health plc From 01/05/21

Experienced financial analyst and biotech executive added to PureTech’s strong leadership team PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discoverin...

PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that members of its management tea...

LYT-200 is a monoclonal antibody designed to block a foundational immunosuppressive protein, galectin-9, which is associated with poor survival rates for a number of cancers Trial will assess safety and tolerability of escalating doses of LYT-200 with results expected in Q4 20...

Study will further evaluate safety and tolerability of LYT-100 and explore clinical efficacy endpoints in patients with breast-cancer related, upper limb secondary lymphedema Previously announced results from multiple ascending dose and food effect study in healthy volunteers ...

Treatment with Follica’s proprietary Hair Follicle Neogenesis stimulation product promoted hair growth Results of the pilot study are encouraging and warrant larger studies in women PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (“PureTech”...

Treatment based on proprietary scalp skin disruption promoted hair growth Results of the pilot study are encouraging and warrant larger studies in women Follica, Inc. (“Follica”), a biotechnology company developing a regenerative platform designed t...

COVID-19 survivors may be at risk for persistent complications, a condition referred to as Long COVID or Long Haul COVID LYT-100, an anti-fibrotic and anti-inflammatory agent, holds potential for treating inflammation and fibrosis implicated in a range of respiratory condition...

Agenda includes expert-led discussions on therapeutic opportunities in the lymphatic system, fibrosis and immuno-oncology P ureTech management to share research and clinical strategies for leveraging leadership in the lymphatic system and related immunology with the potent...

Mr. Ignelzi brings strong financial and operational expertise to the board and will serve as chairman of the Audit Committee Vedanta Biosciences , a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-def...

Mr. Ignelzi brings strong financial and operational expertise to the board and will serve as chairman of the Audit Committee PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company ...